EMA Withdrawn: Esmya (ulipristal acetate) — Gedeon Richter Ltd

View source ↗

Summary

The European Medicines Agency has withdrawn the marketing authorisation for Esmya (ulipristal acetate) by Gedeon Richter Ltd for the treatment of uterine fibroi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Esmya (ulipristal acetate)

Snippet

Status: Withdrawn. Therapeutic area: Leiomyoma. MAH: Gedeon Richter Ltd. Decision date: 11/01/2021